

Biobanking Market - Strategic Insights and Forecasts (2026-2031)

<https://marketpublishers.com/r/B312550C950BEN.html>

Date: April 2026

Pages: 140

Price: US\$ 3,950.00 (Single User License)

ID: B312550C950BEN

Abstracts

The Biobanking market is forecast to grow at a CAGR of 7.8%, reaching USD 105.9 billion in 2031 from USD 72.6 billion in 2026.

The global bio-banking market is a foundational component of modern biomedical research and precision medicine, supporting the collection, processing, storage, and distribution of biological samples such as blood, tissues, and DNA. Bio-banks play a critical role in advancing disease research, drug discovery, and personalized healthcare by enabling access to high-quality biological data. The market is witnessing steady growth due to increasing investments in life sciences research, rising demand for personalized medicine, and expanding applications in genomics and clinical trials. Governments and research institutions are actively supporting the development of large-scale biobanking infrastructures to facilitate long-term health studies and epidemiological research. The integration of advanced data management systems and digital technologies is further enhancing the efficiency and accessibility of bio-banking operations.

Market Drivers

A key driver is the growing demand for personalized medicine. Bio-banks provide essential biological samples and associated data that support the development of targeted therapies and precision diagnostics. This is particularly relevant in oncology, where patient-specific treatments are becoming increasingly important.

The expansion of genomic research is another major growth factor. Advances in sequencing technologies and increasing adoption of genomics in clinical research are driving the need for well-organized and high-quality biological sample repositories. Bio-

banks enable researchers to access diverse datasets required for understanding genetic variations and disease mechanisms.

Increasing investments in biomedical research and clinical trials are also contributing to market growth. Pharmaceutical and biotechnology companies rely on bio-banks to support drug discovery and development processes. Additionally, government initiatives and funding programs are encouraging the establishment of national and regional biobanking networks.

The rising prevalence of chronic diseases is further boosting demand, as long-term studies require extensive biological sample storage and analysis.

Market Restraints

Ethical and legal challenges remain significant constraints. Bio-banking involves the collection and storage of sensitive biological and genetic information, raising concerns related to consent, privacy, and data ownership.

High operational and maintenance costs also pose a challenge. Bio-banks require advanced infrastructure, including temperature-controlled storage systems and sophisticated data management platforms, leading to substantial capital and operational expenses.

Standardization issues further impact market growth. Variations in sample collection, processing, and storage protocols can affect data quality and limit interoperability between different bio-banks.

Technology and Segment Insights

The market is segmented by product type, specimen type, application, and end-user. Equipment such as freezers, storage systems, and automated sample handling solutions represent a significant segment due to the need for reliable and scalable storage infrastructure.

By specimen type, blood and related products hold a dominant share due to their widespread use in research and diagnostics. Tissue samples and DNA are also key segments, supporting applications in genomics and disease research.

In terms of application, drug discovery and clinical research represent major segments.

Bio-banks provide critical resources for identifying biomarkers, validating drug targets, and conducting clinical trials.

End-users include academic and research institutions, pharmaceutical and biotechnology companies, and hospitals. Research institutions account for a significant share due to their active involvement in large-scale studies and collaborations.

Competitive and Strategic Outlook

The competitive landscape is characterized by the presence of specialized bio-banking service providers, research organizations, and technology companies focusing on infrastructure development and service expansion. Key players include Thermo Fisher Scientific, Qiagen, Hamilton Company, Brooks Automation, and Tecan Group.

Strategic initiatives include partnerships between academic institutions and industry players, expansion of biobanking networks, and adoption of advanced automation technologies. Companies are also focusing on improving sample quality, enhancing data integration, and ensuring regulatory compliance to strengthen their market position.

Emerging trends include the integration of artificial intelligence for data analysis, development of virtual bio-banks, and increased focus on large-scale population health studies.

Conclusion

The global bio-banking market is poised for steady growth, driven by increasing demand for personalized medicine, advancements in genomic research, and rising investments in life sciences. While ethical concerns, high costs, and standardization challenges remain key barriers, ongoing technological advancements and collaborative initiatives will support long-term market expansion.

Key Benefits of this Report

Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.

Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.

Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.

Actionable Recommendations: Support strategic decisions to unlock new revenue streams.

Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2025 and forecast data from 2026 to 2031

Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis

Competitive positioning, strategies, and market share evaluation

Revenue growth and forecast assessment across segments and regions

Company profiling including strategies, products, financials, and key developments

Contents

1. INTRODUCTION

- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline

2. RESEARCH METHODOLOGY

- 2.1. Research Data
- 2.2. Assumptions

3. EXECUTIVE SUMMARY

- 3.1. Research Highlights

4. MARKET DYNAMICS

- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Force Analysis
 - 4.3.1. Bargaining Power of Suppliers
 - 4.3.2. Bargaining Power of Buyers
 - 4.3.3. Threat of New Entrants
 - 4.3.4. Threat of Substitutes
 - 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis

5. BIOBANKING MARKET, BY SAMPLE TYPE

- 5.1. Introduction
- 5.2. Blood Products
- 5.3. Human Tissues
- 5.4. Cell Lines

- 5.5. Nucleic Acids
- 5.6. Biological Fluids
- 5.7. Human Waste Products

6. BIOBANKING MARKET, BY OWNERSHIP

- 6.1. Introduction
- 6.2. Universities
- 6.3. National/Regional Agencies
- 6.4. Non-Profit Organizations
- 6.5. Private Organizations

7. BIOBANKING MARKET, BY APPLICATION

- 7.1. Introduction
- 7.2. Regenerative Medicine
- 7.3. Life Science Research
- 7.4. Clinical Research

8. BIOBANKING MARKET, BY END-USE

- 8.1. Introduction
- 8.2. Pharmaceutical Companies
- 8.3. Academic and Research Institutes
- 8.4. Hospitals

9. BIOBANKING MARKET, BY GEOGRAPHY

- 9.1. Introduction
- 9.2. North America
 - 9.2.1. United States
 - 9.2.2. Canada
 - 9.2.3. Mexico
- 9.3. South America
 - 9.3.1. Brazil
 - 9.3.2. Argentina
 - 9.3.3. Others
- 9.4. Europe
 - 9.4.1. United Kingdom

- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
- 9.5. The Middle East and Africa
 - 9.5.1. Saudi Arabia
 - 9.5.2. UAE
 - 9.5.3. Israel
 - 9.5.4. Others
- 9.6. Asia Pacific
 - 9.6.1. Japan
 - 9.6.2. China
 - 9.6.3. India
 - 9.6.4. South Korea
 - 9.6.5. Indonesia
 - 9.6.6. Thailand
 - 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

- 10.1. Major Players and Strategy Analysis
- 10.2. Market Share Analysis
- 10.3. Mergers, Acquisitions, Agreements, and Collaborations

11. COMPANY PROFILES

- 11.1. Sapien Biosciences
- 11.2. Hamilton Company
- 11.3. UK Biobank
- 11.4. Apollo Hospitals
- 11.5. Banka Bio
- 11.6. Labvantage
- 11.7. Amgen
- 11.8. BioKryo
- 11.9. Thermo Fisher Scientific
- 11.10. Cureline

I would like to order

Product name: Biobanking Market - Strategic Insights and Forecasts (2026-2031)

Product link: <https://marketpublishers.com/r/B312550C950BEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B312550C950BEN.html>